Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second IVIg dose in Guillain-Barré syndrome patients with poor prognosis
NL-OMON22921Active, not recruiting
- Sponsor
- Erasmus MC Rotterdam
- Start
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of Nanogam and Placebo-COD Research Private Ltd in Guillain-Barré syndrome (GBS) (3 arms), sponsored by Erasmus MC Rotterdam. Primary endpoint: Functional outcome at 4 weeks. Started Feb 2010; status: active, not recruiting.
02
Drugs
NanogamPlacebo-COD Research Private Ltd
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NL-OMON22921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22921.